Clinical trial results:
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction And Maintenance Treatment For Patients With Moderately to Severely Active Crohn's Disease

Summary

EudraCT number	2014-003824-36
Trial protocol	SE EE LT LV HU DE ES CZ NL AT SK BE FR HR RO IT
Global end of trial date	07 September 2021

Results information

Result version number	v2 (current)
This version publication date	06 January 2023
First version publication date	17 September 2022
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	GA29144

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03850535
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124., Basel, Switzerland, CH-4070
Public contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 September 2021
Is this the analysis of the primary completion data?	Yes
Primary completion date	07 September 2021
Global end of trial reached?	Yes
Global end of trial date	07 September 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

A study evaluating the efficacy, safety, and tolerability of etrolizumab compared with placebo during induction and maintenance treatment of moderately to severely active Crohn's Disease (CD)

Protection of trial subjects:

The study was conducted in accordance with the principles of the "Declaration of Helsinki" and Good Clinical Practice (GCP) guidelines according to the regulations and procedures described in the protocol.

Background therapy: -

Evidence for comparator:

No active control

Actual start date of recruitment	20 March 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 1
Country: Number of subjects enrolled	Austria: 15
Country: Number of subjects enrolled	Australia: 42
Country: Number of subjects enrolled	Belgium: 11
Country: Number of subjects enrolled	Brazil: 40
Country: Number of subjects enrolled	Bulgaria: 8
Country: Number of subjects enrolled	Canada: 64
Country: Number of subjects enrolled	Switzerland: 9
Country: Number of subjects enrolled	Czechia: 55
Country: Number of subjects enrolled	Germany: 29
Country: Number of subjects enrolled	Spain: 36
Country: Number of subjects enrolled	Estonia: 4
Country: Number of subjects enrolled	France: 58
Country: Number of subjects enrolled	United Kingdom: 34
Country: Number of subjects enrolled	Croatia: 9
Country: Number of subjects enrolled	Hungary: 38
Country: Number of subjects enrolled	Israel: 22
Country: Number of subjects enrolled	Italy: 22
Country: Number of subjects enrolled	Korea, Republic of: 34
Country: Number of subjects enrolled	Lithuania: 6

Country: Number of subjects enrolled	Latvia: 4
Country: Number of subjects enrolled	Mexico: 4
Country: Number of subjects enrolled	Netherlands: 21
Country: Number of subjects enrolled	New Zealand: 22
Country: Number of subjects enrolled	Poland: 60
Country: Number of subjects enrolled	Romania: 13
Country: Number of subjects enrolled	Russian Federation: 69
Country: Number of subjects enrolled	Serbia: 15
Country: Number of subjects enrolled	Slovakia: 13
Country: Number of subjects enrolled	Turkey: 12
Country: Number of subjects enrolled	Ukraine: 39
Country: Number of subjects enrolled	United States: 221
Country: Number of subjects enrolled	South Africa: 5
Worldwide total number of subjects	1035
EEA total number of subjects	402

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	997
From 65 to 84 years	38
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

At the time of study closure, a total of 1035 patients were randomized into the induction phase, enrolled sequentially across Cohorts 1, 2, and 3. The final sample size for the pivotal induction Cohort 3 was lower than the 496 patients planned per the final protocol due to the early closure of the study. Cohorts below are mutually exclusive.

Pre-assignment

Screening details:

A total of 1035 participants entered the study across induction cohorts 1-3, a subset of 487 patients moved into the maintenance phase of the study.

Period 1

Period 1 title	Induction Phase
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer, Data analyst, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo Cohort 1

Arm description:

Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm received two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.

Arm type	Placebo
Investigational medicinal product name	Two SC injections of etrolizumab-matching placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo

Arm title	Etrolizumab 105mg Cohort 1

Arm description:

Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm received one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Arm type	Experimental
Investigational medicinal product name	Etrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

One SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week

Arm title	Etrolizumab 210mg Cohort 1

Arm description:

Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm received one SC injection of etrolizumab (210 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Arm type	Experimental
Investigational medicinal product name	Etrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

One subcutaneous (SC) injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Arm title	Etrolizumab 105mg Cohort 2

Arm description:

Cohort 2 enrolled participants after Cohort 1 and was considered a "feeder" cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm received one SC injection of open-label etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Arm type	Experimental
Investigational medicinal product name	Etrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

One SC injection of open-label etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Arm title	Etrolizumab 210mg Cohort 2

Arm description:

Cohort 2 enrolled participants after Cohort 1 and was considered a "feeder" cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm received one SC injection of open-label etrolizumab (210 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Arm type	Experimental
Investigational medicinal product name	Etrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

one SC injection of open-label etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking for the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Arm title	Placebo Cohort 3

Arm description:

Cohort 3 was the last to enroll participants (after Cohort 2) and was the pivotal cohort for the Induction Phase. Participants randomized to this arm received two SC injections of etrolizumab-matching placebo

at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.

Arm type	Placebo
Investigational medicinal product name	Etrolizumab-matching placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week

Arm title	Etrolizumab 105mg Cohort 3

Arm description:

Cohort 3 was the last to enroll participants (after Cohort 2) and was the pivotal cohort for the Induction Phase. Participants randomized to this arm received one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Arm type	Experimental
Investigational medicinal product name	Etrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

One SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Arm title	Etrolizumab 210mg Cohort 3

Arm description:

Cohort 3 was the last to enroll participants (after Cohort 2) and was the pivotal cohort for the Induction Phase. Participants randomized to this arm received one SC injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Arm type	Experimental
Investigational medicinal product name	Etrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

One SC injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Number of subjects in period 1	Placebo Cohort 1	Etrolizumab 105mg Cohort 1	Etrolizumab 210mg Cohort 1
Started	59	120	121
Completed	52	104	108
Not completed	7	16	13
Lack of calculation	-	-	-

Consent withdrawn by subject	1	2	4
Physician decision	-	-	1
Adverse Event	2	4	1
Early withdrawal and roll over to different study	-	-	-
Non-compliance	-	1	3
Lost to follow-up	1	-	-
Sponsor decision	-	1	2
Technical reason	-	-	-
Lack of efficacy	3	6	2
Protocol deviation	-	2	-

Number of subjects in period 1	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2	Placebo Cohort 3
Started	176	174	97
Completed	141	145	80
Not completed	35	29	17
Lack of calculation	-	-	-
Consent withdrawn by subject	6	7	4
Physician decision	4	-	2
Adverse Event	2	5	2
Early withdrawal and roll over to different study	-	-	-
Non-compliance	1	3	-
Lost to follow-up	1	-	-
Sponsor decision	-	-	-
Technical reason	1	-	-
Lack of efficacy	17	14	8
Protocol deviation	3	-	1

Number of subjects in period 1	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3
Started	143	145
Completed	118	114
Not completed	25	31
Lack of calculation	-	1
Consent withdrawn by subject	3	6
Physician decision	1	-
Adverse Event	-	-
Early withdrawal and roll over to different study	1	-
Non-compliance	1	1
Lost to follow-up	1	-
Sponsor decision	-	-
Technical reason	-	-

Lack of efficacy	17	23
Protocol deviation	1	-

Period 2

Period 2 title	Maintenance Phase
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer, Data analyst, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo/Placebo

Arm description:

Participants who received placebo during the Induction Phase (from Cohorts 1 and 3) and achieved a CDAI-70 response at Week 14 underwent a sham randomization into the Maintenance Phase. Placebo responders from induction received blinded maintenance treatment with an SC injection of placebo once every 4 weeks (q4w) from Week 16 to Week 64.

Arm type	Placebo
Investigational medicinal product name	matching Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

placebo during the Induction Phase (from Cohorts 1 and 3) and achieved a CDAI-70 response at Week 14 will undergo a sham randomization into the Maintenance Phase. Placebo responders from induction will receive blinded maintenance treatment with an SC injection of placebo once every 4 weeks (q4w) from Week 16 to Week 64.

Arm title	Etrolizumab/Placebo

Arm description:

Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy were re-randomized into the Maintenance Phase. Etrolizumab responders from induction who were re-randomized to this arm received blinded maintenance treatment with an SC injection of placebo q4w from Week 16 to Week 64.

Arm type	Experimental
Investigational medicinal product name	Erolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm received blinded maintenance treatment with an SC injection of placebo q4w from Week 16 to Week 64.

Arm title	Etrolizumab/Etrolizumab 105mg

Arm description:

Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy were re-randomized into the Maintenance Phase. Etrolizumab responders from induction who were re-randomized to this arm received blinded maintenance treatment with an SC injection of etrolizumab (105 mg) q4w from Week 16 to Week 64.

Arm type	Experimental
Investigational medicinal product name	Etrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm received blinded maintenance treatment with an SC injection of etrolizumab (105 mg) q4w from Week 16 to Week 64.

Number of subjects in period 2[1]	Placebo/Placebo	Etrolizumab/Placebo	Etrolizumab/Etrolizumab 105mg
Started	53	217	217
Completed	41	175	165
Not completed	12	42	52
Adverse event, serious fatal	-	-	1
Physician decision	1	3	2
Adverse event, non-fatal	1	1	3
Withdrawal by Subject	3	12	12
Site closure	-	1	-
Lack of efficacy	7	25	33
Protocol deviation	-	-	1

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Only participants from the induction phase who had achieved a CDAI-70 response at Week 14 without the use of rescue therapy were enrolled in the maintenance phase.

Baseline characteristics

Reporting groups

Reporting group title	Placebo Cohort 1

Reporting group description:

Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm received two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.

Reporting group title	Etrolizumab 105mg Cohort 1

Reporting group description:

Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm received one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Etrolizumab 210mg Cohort 1

Reporting group description:

Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm received one SC injection of etrolizumab (210 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Etrolizumab 105mg Cohort 2

Reporting group description:

Cohort 2 enrolled participants after Cohort 1 and was considered a "feeder" cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm received one SC injection of open-label etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Etrolizumab 210mg Cohort 2

Reporting group description:

Cohort 2 enrolled participants after Cohort 1 and was considered a "feeder" cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm received one SC injection of open-label etrolizumab (210 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Placebo Cohort 3

Reporting group description:

Cohort 3 was the last to enroll participants (after Cohort 2) and was the pivotal cohort for the Induction Phase. Participants randomized to this arm received two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.

Reporting group title	Etrolizumab 105mg Cohort 3

Reporting group description:

Cohort 3 was the last to enroll participants (after Cohort 2) and was the pivotal cohort for the Induction Phase. Participants randomized to this arm received one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Etrolizumab 210mg Cohort 3

Reporting group description:

Cohort 3 was the last to enroll participants (after Cohort 2) and was the pivotal cohort for the Induction Phase. Participants randomized to this arm received one SC injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group values	Placebo Cohort 1	Etrolizumab 105mg Cohort 1	Etrolizumab 210mg Cohort 1
Number of subjects	59	120	121
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	57	116	118
From 65-84 years	2	4	3
85 years and over	0	0	0
Age Continuous			
Units: Years			
arithmetic mean	36.5	38.9	38.6
standard deviation	± 12.7	± 13.1	± 13.4
Sex: Female, Male			
Units: Participants			
Female	31	57	68
Male	28	63	53
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	2	5	5
Not Hispanic or Latino	53	110	113
Unknown or Not Reported	4	5	3
Race/Ethnicity, Customized			
race			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	5	9	7
Black or African American	3	5	2
White	46	96	104
Other	5	10	8

Reporting group values	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2	Placebo Cohort 3
Number of subjects	176	174	97
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0

Adults (18-64 years)	169	166	93
From 65-84 years	7	8	4
85 years and over	0	0	0
Age Continuous			
Units: Years			
arithmetic mean	38.4	38.2	37.1
standard deviation	± 13.3	± 13.2	± 13.6
Sex: Female, Male			
Units: Participants			
Female	80	80	38
Male	96	94	59
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	7	8	15
Not Hispanic or Latino	160	154	75
Unknown or Not Reported	9	12	7
Race/Ethnicity, Customized			
race			
Units: Subjects			
American Indian or Alaska Native	0	0	1
Asian	8	14	0
Black or African American	1	5	6
White	153	141	81
Other	14	14	9

Reporting group values	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3	Total
Number of subjects	143	145	1035
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	137	141	997
From 65-84 years	6	4	38
85 years and over	0	0	0
Age Continuous			
Units: Years			
arithmetic mean	38.3	36.5	
standard deviation	± 13.4	± 13.1	-
Sex: Female, Male			
Units: Participants			
Female	69	69	492
Male	74	76	543
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	13	7	62

Not Hispanic or Latino	126	129	920
Unknown or Not Reported	4	9	53
Race/Ethnicity, Customized			
race			
Units: Subjects			
American Indian or Alaska Native	3	0	4
Asian	4	2	49
Black or African American	8	2	32
White	117	128	866
Other	11	13	84

End points

End points reporting groups

Reporting group title	Placebo Cohort 1

Reporting group description:

Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm received two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.

Reporting group title	Etrolizumab 105mg Cohort 1

Reporting group description:

Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm received one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Etrolizumab 210mg Cohort 1

Reporting group description:

Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm received one SC injection of etrolizumab (210 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Etrolizumab 105mg Cohort 2

Reporting group description:

Cohort 2 enrolled participants after Cohort 1 and was considered a "feeder" cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm received one SC injection of open-label etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Etrolizumab 210mg Cohort 2

Reporting group description:

Cohort 2 enrolled participants after Cohort 1 and was considered a "feeder" cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm received one SC injection of open-label etrolizumab (210 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Placebo Cohort 3

Reporting group description:

Cohort 3 was the last to enroll participants (after Cohort 2) and was the pivotal cohort for the Induction Phase. Participants randomized to this arm received two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.

Reporting group title	Etrolizumab 105mg Cohort 3

Reporting group description:

Cohort 3 was the last to enroll participants (after Cohort 2) and was the pivotal cohort for the Induction Phase. Participants randomized to this arm received one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Etrolizumab 210mg Cohort 3

Reporting group description:

Cohort 3 was the last to enroll participants (after Cohort 2) and was the pivotal cohort for the Induction Phase. Participants randomized to this arm received one SC injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Placebo/Placebo

Reporting group description:

Participants who received placebo during the Induction Phase (from Cohorts 1 and 3) and achieved a CDAI-70 response at Week 14 underwent a sham randomization into the Maintenance Phase. Placebo responders from induction received blinded maintenance treatment with an SC injection of placebo once every 4 weeks (q4w) from Week 16 to Week 64.

Reporting group title	Etrolizumab/Placebo

Reporting group description:

Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy were re-randomized into the Maintenance Phase. Etrolizumab responders from induction who were re-randomized to this arm received blinded maintenance treatment with an SC injection of placebo q4w from Week 16 to Week 64.

Reporting group title	Etrolizumab/Etrolizumab 105mg

Reporting group description:

Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy were re-randomized into the Maintenance Phase. Etrolizumab responders from induction who were re-randomized to this arm received blinded maintenance treatment with an SC injection of etrolizumab (105 mg) q4w from Week 16 to Week 64.

Subject analysis set title	Maintenance Phase - Etrolizumab 105 mg/ Etrolizumab 105 mg
Subject analysis set type	Modified intention-to-treat

Subject analysis set description:

Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of etrolizumab (105 mg) q4w from Week 16 to Week 64.

Subject analysis set title	Maintenance Phase - Etrolizumab 210 mg/ Etrolizumab 105 mg
Subject analysis set type	Modified intention-to-treat

Subject analysis set description:

Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of etrolizumab (105 mg) q4w from Week 16 to Week 64.

Subject analysis set title	Etro 105mg Induction Only Cohort
Subject analysis set type	Modified intention-to-treat

Subject analysis set description:

Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8 and 12

Subject analysis set title	Etro 210mg Induction Only Cohort
Subject analysis set type	Modified intention-to-treat

Subject analysis set description:

Participants randomized to this arm will receive one SC injection of etrolizumab (210 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8 and 12

Subject analysis set title	Etro 105/ Placebo Induction and Maintenance Phase Cohort
Subject analysis set type	Modified intention-to-treat

Subject analysis set description:

Participants who received etrolizumab 105 mg during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy that were re-randomized into the Mainetnance Phase. Etrolizumab responders from induction who re re-randomized to this arm received blinded maintenance treatment with an SC injection of placebo q4w from Week 16 to Week 64

Subject analysis set title	Etro 210/ Placebo Induction and Maintenance Phase
Subject analysis set type	Modified intention-to-treat

Subject analysis set description:

Participants who received etrolizumab 210 mg during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy that were re-randomized

into the Maintenance Phase. Etrolizumab responders from induction who were re-randomized to this arm received blinded maintenance treatment with an SC injection of placebo q4w from Week 16 to Week 64

Subject analysis set title	Etro 105/Etro 105 Induction and Maintenance Phase
Subject analysis set type	Modified intention-to-treat

Subject analysis set description:

Participants who received etrolizumab 105mg during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy that were re-randomized into the Maintenance Phase. Etrolizumab responders from induction who were re-randomized to this arm received blinded maintenance treatment with an SC injection of etrolizumab 105mg q4w from Week 16 to Week 64

Subject analysis set title	Etro 210/Etro 105 Induction and Maintenance Phase
Subject analysis set type	Modified intention-to-treat

Subject analysis set description:

Participants who received etrolizumab 210mg during the Induction Phase (from Cohorts 1-3) and achieved CDAI-70 response at Week 14 without the use of rescue therapy that were re-randomized into the Maintenance Phase. Etrolizumab responders from induction who were re-randomized to this arm received blinded maintenance treatment with an SC injection of etrolizumab 105mg q4w from Week 16 to Week 64

Primary: Induction Phase: Cohort 1: Percentage of Participants with Clinical Remission at Week 14

End point title	Induction Phase: Cohort 1: Percentage of Participants with Clinical Remission at Week 14[1][2]

End point description:

Clinical remission is defined as liquid/soft stool frequency (SF) mean daily score less than or equal (≤)3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit. mITT - Modified Intent to Treat population: all patients randomized who received at least one dose of study drug, grouped under the randomized treatment arm. Results for Induction Phase Cohort 2 and 3 and Maintenance Phase are not presented.

End point type	Primary

End point timeframe:

Week 14

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The induction data from Cohort 1 was exploratory in nature and was evaluated prior to the commencement of enrollment to the pivotal Induction Phase of Cohort 3.
[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: 90% confidence interval was reported for induction phase cohort 1 participants. For induction phase cohort 2 and 3 participants, 95% confidence interval was reported, hence the data is reported as a separate outcome measure for cohort 1. The participants in the maintenance phase were not analyzed for this outcome measure.

End point values	Placebo Cohort 1	Etrolizumab 105mg Cohort 1	Etrolizumab 210mg Cohort 1	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	59	120	121	
Units: Percentage of Particiapnts				
number (confidence interval 90%)	11.9 (6.56 to 20.51)	20.00 (14.69 to 26.64)	27.3 (21.16 to 34.37)	

Statistical analyses

No statistical analyses for this end point

Primary: Induction Phase: Cohort 2 and 3: Percentage of Participants with Clinical Remission at Week 14

End point title	Induction Phase: Cohort 2 and 3: Percentage of Participants with Clinical Remission at Week 14[3]

End point description:

Clinical remission is defined as liquid/soft stool frequency (SF) mean daily score less than or equal (≤)3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit. mITT - Modified Intent to Treat population: all patients randomized who received at least one dose of study drug, grouped under the randomized treatment arm. Results for Induction Phase Cohort 1 is not presented.

End point type	Primary

End point timeframe:

Week 14

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: 90% confidence interval was reported for induction phase cohort 1 participants. For induction phase cohort 2 and 3 participants, 95% confidence interval was reported, hence the data is reported as a separate outcome measure for cohorts 2 and 3. The participants in the maintenance phase were not analyzed for this outcome measure.

End point values	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2	Placebo Cohort 3	Etrolizumab 105mg Cohort 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	176	174	96	143
Units: Percentage of Particiapnts				
number (confidence interval 95%)	29.5 (23.30 to 36.66)	29.3 (23.05 to 36.46)	29.2 (21.02 to 38.92)	30.1 (23.16 to 38.03)

End point values	Etrolizumab 210mg Cohort 3			
Subject group type	Reporting group			
Number of subjects analysed	145			
Units: Percentage of Particiapnts				
number (confidence interval 95%)	33.1 (25.97 to 41.11)			

Statistical analyses

Statistical analysis title	Clinical Remission at Week 14

Statistical analysis description:

Percentage of Participants with Clinical Remission at Week 14

Comparison groups	Etrolizumab 105mg Cohort 3 v Placebo Cohort 3

Number of subjects included in analysis	239
Analysis specification	Pre-specified
Analysis type	superiority[4]
P-value	= 0.8508 [5]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in rate
Point estimate	1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.85
upper limit	12.56

Notes:

[4] - Difference in remission rates is adjusted using CMH weights and the 95% CIs use the Newcombes method.
[5] - The multiplicity-adjusted p-values are presented.

Statistical analysis title	Clinical Remission at Week 14

Statistical analysis description:

Percentage of Participants with Clinical Remission at Week 14

Comparison groups	Placebo Cohort 3 v Etrolizumab 210mg Cohort 3
Number of subjects included in analysis	241
Analysis specification	Pre-specified
Analysis type	superiority[6]
P-value	= 0.5235 [7]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in rate
Point estimate	3.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.3
upper limit	15.27

Notes:

[6] - Difference in remission rates is adjusted using CMH weights and the 95% CIs use the Newcombes method.
[7] - The multiplicity adjusted p-values are presented.

Primary: Induction Phase: Cohort 1: Percentage of Participants with Endoscopic Improvement at Week 14

End point title	Induction Phase: Cohort 1: Percentage of Participants with Endoscopic Improvement at Week 14[8][9]

End point description:

Endoscopic improvement is defined as 50 percent (%) reduction from baseline in Simplified Endoscopic Index for Crohn’s Disease (SES-CD) score. mITT. Results for Induction Phase Cohort 2 and 3 and Maintenance Phase are not presented.

End point type	Primary

End point timeframe:

Week 14

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The induction data from Cohort 1 was exploratory in nature and was evaluated prior to the commencement of enrollment to the pivotal Induction Phase of Cohort 3.

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: 90% confidence interval was reported for induction phase cohort 1 participants. For induction phase cohort 2 and 3 participants, 95% confidence interval was reported, hence the data is reported as a separate outcome measure for cohort 1. The participants in the maintenance phase were not analyzed for this outcome measure.

End point values	Placebo Cohort 1	Etrolizumab 105mg Cohort 1	Etrolizumab 210mg Cohort 1	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	59	120	121	
Units: Percentage of Participants				
number (confidence interval 90%)	3.4 (-1.74 to 8.52)	19.5 (12.37 to 26.64)	16.8 (10.11 to 23.50)	

Statistical analyses

No statistical analyses for this end point

Primary: Induction Phase: Cohort 2 and 3: Percentage of Participants with Endoscopic Improvement at Week 14

End point title	Induction Phase: Cohort 2 and 3: Percentage of Participants with Endoscopic Improvement at Week 14[10]

End point description:

Endoscopic improvement is defined as 50 percent (%) reduction from baseline in Simplified Endoscopic Index for Crohn's Disease (SES-CD) score. mITT. Results for Induction Phase Cohort 1 and Maintenance Phase are not presented.

End point type	Primary

End point timeframe:

Week 14

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: 90% confidence interval was reported for induction phase cohort 1 participants. For induction phase cohort 2 and 3 participants, 95% confidence interval was reported, hence the data is reported as a separate outcome measure for cohorts 2 and 3. The participants in the maintenance phase were not analyzed for this outcome measure.

End point values	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2	Placebo Cohort 3	Etrolizumab 105mg Cohort 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	176	174	96	143
Units: Percentage of Participants				
number (confidence interval 95%)	20.8 (14.81 to 26.86)	22.2 (16.02 to 28.35)	21.6 (13.24 to 29.95)	26.2 (18.96 to 33.44)

End point values	Etrolizumab 210mg Cohort 3			

Subject group type	Reporting group			
Number of subjects analysed	145			
Units: Percentage of Participants				
number (confidence interval 95%)	27.4 (20.01 to 34.79)			

Statistical analyses

Statistical analysis title	Endoscopic Improvement at Week 14
Statistical analysis description:	
Percentage of Participants With Endoscopic Improvement at Week 14	
Comparison groups	Placebo Cohort 3 v Etrolizumab 210mg Cohort 3
Number of subjects included in analysis	241
Analysis specification	Pre-specified
Analysis type	superiority[11]
P-value	= 0.317 [12]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in rate
Point estimate	5.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.43
upper limit	17.05

Notes:

[11] - Difference in response rates is adjusted using CMH weights and the 95% CIs use the Newcombes method.
[12] - The multiplicity adjusted p-values are presented.

Statistical analysis title	Endoscopic Improvement at Week 14
Statistical analysis description:	
Percentage of Participants With Endoscopic Improvement at Week 14	
Comparison groups	Placebo Cohort 3 v Etrolizumab 105mg Cohort 3
Number of subjects included in analysis	239
Analysis specification	Pre-specified
Analysis type	superiority[13]
P-value	= 0.7908 [14]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in rate
Point estimate	4.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.26
upper limit	16.11

Notes:

[13] - Difference in response rates is adjusted using CMH weights and the 95% CIs use the Newcombes method.
[14] - The multiplicity adjusted p-values are presented.

Primary: Maintenance Phase: Percentage of Participants with Clinical Remission at

Week 66

End point title	Maintenance Phase: Percentage of Participants with Clinical Remission at Week 66

End point description:

Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit. Maintenance Phase Placebo/Placebo cohort is not reported since this is an exploratory population only. Results for the Induction phase populations for cohorts 1-3 are not presented.

End point type	Primary

End point timeframe:

Baseline and Week 66

End point values	Etrolizumab/Placebo	Etrolizumab/Etrolizumab 105mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	217	217		
Units: percentage of participants				
number (confidence interval 95%)	24.00 (18.77 to 30.06)	35.00 (28.99 to 41.58)		

Statistical analyses

Statistical analysis title	Participants with Clinical Remission Week 66

Statistical analysis description:

Percentage of Participants with Clinical Remission at Week 66

Comparison groups	Etrolizumab/Placebo v Etrolizumab/Etrolizumab 105mg
Number of subjects included in analysis	434
Analysis specification	Pre-specified
Analysis type	superiority[15]
P-value	= 0.0088 [16]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in rate
Point estimate	11.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.7
upper limit	19.65

Notes:

[15] - Difference in response rates is adjusted using CMH weights and the 95% CIs use the Newcombes method.

[16] - The multiplicity adjusted p-values are presented.

Primary: Maintenance Phase: Percentage of Participants with Endoscopic Improvement at Week 66

End point title	Maintenance Phase: Percentage of Participants with Endoscopic Improvement at Week 66

End point description:

Endoscopic improvement is defined as 50% reduction from baseline in SES-CD score. mITT. Maintenance Phase Placebo/Placebo cohort is not reported since this is an exploratory population only. Induction Phase population for cohorts 1-3 are not included.

End point type	Primary

End point timeframe:

Week 66

End point values	Etrolizumab/Placebo	Etrolizumab/Etrolizumab 105mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	217	217		
Units: Percentage of Participants				
number (confidence interval 95%)	12.2 (7.71 to 16.69)	23.6 (17.90 to 29.29)		

Statistical analyses

Statistical analysis title	Participants with Endoscopic Improvement Week 66

Statistical analysis description:

Percentage of Participants with Endoscopic Improvement at Week 66

Comparison groups	Etrolizumab/Placebo v Etrolizumab/Etrolizumab 105mg
Number of subjects included in analysis	434
Analysis specification	Pre-specified
Analysis type	superiority[17]
P-value	= 0.0026 [18]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in rate
Point estimate	11.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.11
upper limit	18.83

Notes:

[17] - Difference in response rates is adjusted using CMH weights and the 95% CIs use the Newcombes method.
[18] - The multiplicity adjusted p-values are presented.

Secondary: Induction Phase: Cohort 1: Percentage of Participants with Clinical Remission at Week 6

End point title	Induction Phase: Cohort 1: Percentage of Participants with Clinical Remission at Week 6[19]

End point description:

Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit. mITT. Results for Induction Phase Cohort 2 and 3 and Maintenance Phase are not presented.

End point type	Secondary

End point timeframe:

Week 6

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: 90% confidence interval was reported for induction phase cohort 1 participants. For induction phase cohort 2 and 3 participants, 95% confidence interval was reported, hence the data is reported as a separate outcome measure for cohort 1. The participants in the maintenance phase were not analyzed for this outcome measure.

End point values	Placebo Cohort 1	Etrolizumab 105mg Cohort 1	Etrolizumab 210mg Cohort 1	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	59	120	121	
Units: Percentage of participants				
number (confidence interval 90%)	5.1 (2.05 to 12.06)	15.0 (10.41 to 21.13)	24.8 (18.93 to 31.75)	

Statistical analyses

No statistical analyses for this end point

Secondary: Induction Phase: Cohort 2 and 3: Percentage of Participants with Clinical Remission at Week 6

End point title	Induction Phase: Cohort 2 and 3: Percentage of Participants with Clinical Remission at Week 6[20]

End point description:

Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit. mITT. Results for Induction Phase Cohort 1 and Maintenance Phase are not presented.

End point type	Secondary

End point timeframe:

Week 6

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: 90% confidence interval was reported for induction phase cohort 1 participants. For induction phase cohort 2 and 3 participants, 95% confidence interval was reported, hence the data is reported as a separate outcome measure for cohorts 2 and 3. The participants in the maintenance phase were not analyzed for this outcome measure.

End point values	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2	Placebo Cohort 3	Etrolizumab 105mg Cohort 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	176	174	96	143
Units: percentage of participants				
number (confidence interval 95%)	20.5 (15.16 to 27.01)	21.3 (15.84 to 27.93)	20.8 (13.91 to 30.00)	23.8 (17.54 to 31.38)

End point values	Etrolizumab 210mg Cohort 3			
Subject group type	Reporting group			
Number of subjects analysed	145			
Units: percentage of participants				
number (confidence interval 95%)	23.4 (17.29 to 30.97)			

Statistical analyses

Statistical analysis title	Clinical Remission at Week 6
Statistical analysis description:	
Percentage of Participants With Clinical Remission at Week 6	
Comparison groups	Placebo Cohort 3 v Etrolizumab 105mg Cohort 3
Number of subjects included in analysis	239
Analysis specification	Pre-specified
Analysis type	superiority[21]
P-value	= 1 [22]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in rate
Point estimate	3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.02
upper limit	13.45

Notes:

[21] - Difference in remission rates are adjusted using CMH weights and the 95% CIs use the Newcombes method.

[22] - The multiplicity adjusted p-values are presented.

Statistical analysis title	Clinical Remission at Week 6
Statistical analysis description:	
Percentage of Participants With Clinical Remission at Week 6	
Comparison groups	Placebo Cohort 3 v Etrolizumab 210mg Cohort 3
Number of subjects included in analysis	241
Analysis specification	Pre-specified
Analysis type	superiority[23]
P-value	= 0.7908 [24]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in rate
Point estimate	2.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.78
upper limit	12.56

Notes:

[23] - Difference in remission rates are adjusted using CMH weights and the 95% CIs use the Newcombes method.
[24] - The multiplicity adjusted p-values are presented.

Secondary: Induction Phase: Cohort 1: Percentage of Participants with SES-CD Score ≤4 (≤2 for Ileal Participants), with No Segment Having a Subcategory Score Greater than (>)1, at Week 14

End point title	Induction Phase: Cohort 1: Percentage of Participants with SES-CD Score ≤4 (≤2 for Ileal Participants), with No Segment Having a Subcategory Score Greater than (>)1, at Week 14[25]

End point description:

Endoscopic Remission is defined as SES-CD total score <=4 (<=2 for ileal only patients), with no segment having a subcategory score >1. SES-CD = Simple Endoscopic Score for Crohn's Disease. A composite of four assessments, each rated from 0 to 3: size of ulcers, proportion of the surface covered by ulcers, proportion of the surface with any other lesions, and presence of narrowings (stenosis). The SES-CD total score ranges from 0 to 60, a higher score indicates worse disease activity. mITT. Results for Induction Phase Cohort 2 and 3 and Maintenance Phase are not presented.

End point type	Secondary

End point timeframe:

Week 14

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: 90% confidence interval was reported for induction phase cohort 1 participants. For induction phase cohort 2 and 3 participants, 95% confidence interval was reported, hence the data is reported as a separate outcome measure for cohort 1. The participants in the maintenance phase were not analyzed for this outcome measure.

End point values	Placebo Cohort 1	Etrolizumab 105mg Cohort 1	Etrolizumab 210mg Cohort 1	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	59	120	121	
Units: Percentage of participants				
number (confidence interval 90%)	1.7 (-2.40 to 5.79)	13.8 (7.53 to 20.14)	8.3 (3.29 to 13.24)	

Statistical analyses

No statistical analyses for this end point

Secondary: Induction Phase: Cohort 2 and 3: Percentage of Participants with SES-CD Score ≤4 (≤2 for Ileal Participants), with No Segment Having a Subcategory Score Greater than (>)1, at Week 14

End point title	Induction Phase: Cohort 2 and 3: Percentage of Participants with SES-CD Score ≤4 (≤2 for Ileal Participants), with No Segment Having a Subcategory Score Greater than (>)1, at Week 14[26]

End point description:

Endoscopic Remission is defined as SES-CD total score <=4 (<=2 for ileal only patients), with no segment having a subcategory score >1. SES-CD = Simple Endoscopic Score for Crohn's Disease. A composite of four assessments, each rated from 0 to 3: size of ulcers, proportion of the surface covered by ulcers, proportion of the surface with any other lesions, and presence of narrowings (stenosis). The SES-CD total score ranges from 0 to 60, a higher score indicates worse disease activity. mITT. Results for Induction Phase Cohort 1 and Maintenance Phase are not presented.

End point type	Secondary

End point timeframe:

Week 14

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: 90% confidence interval was reported for induction phase cohort 1 participants. For induction phase cohort 2 and 3 participants, 95% confidence interval was reported, hence the data is reported as a separate outcome measure for cohorts 2 and 3. The participants in the maintenance phase were not analyzed for this outcome measure.

End point values	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2	Placebo Cohort 3	Etrolizumab 105mg Cohort 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	176	174	96	142
Units: percentage of participants				
number (confidence interval 95%)	9.9 (5.43 to 14.42)	12.3 (5.43 to 14.42)	8.7 (2.84 to 14.52)	10.2 (5.15 to 15.27)

End point values	Etrolizumab 210mg Cohort 3			
Subject group type	Reporting group			
Number of subjects analysed	145			
Units: percentage of participants				
number (confidence interval 95%)	15.3 (9.33 to 21.29)			

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Percentage of Participants with SES-CD Score ≤4

Comparison groups	Placebo Cohort 3 v Etrolizumab 105mg Cohort 3
Number of subjects included in analysis	238
Analysis specification	Pre-specified
Analysis type	superiority[27]
P-value	= 1 [28]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in rate
Point estimate	1.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.51
upper limit	9.73

Notes:

[27] - Difference in remission rates are adjusted using CMH weights and the 95% CIs use the Newcombes method.
[28] - The multiplicity adjusted p-values are presented.

Statistical analysis title	Statistical Analysis 2
Comparison groups	Placebo Cohort 3 v Etrolizumab 210mg Cohort 3
Number of subjects included in analysis	241
Analysis specification	Pre-specified
Analysis type	superiority[29]
P-value	= 0.5235 [30]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in rate
Point estimate	6.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.24
upper limit	15.16

Notes:

[29] - Difference in remission rates are adjusted using CMH weights and the 95% CIs use the Newcombes method.
[30] - The multiplicity adjusted p-values are presented.

Secondary: Induction Phase: Cohort 1: Change from Baseline in Crohn's Disease-Patient-Reported Outcome Signs and Symptoms (CD-PRO/SS) Score at Week 14

End point title	Induction Phase: Cohort 1: Change from Baseline in Crohn's Disease-Patient-Reported Outcome Signs and Symptoms (CD-PRO/SS) Score at Week 14[31]

End point description:

CD-PRO/SS: Crohn's Disease Patient Reported Outcomes Signs and Symptoms. For each item, the score is taken as the average across 4-7 days eDiary data within a 9 day window from visit, else the score is considered missing. The CD-PRO/SS Bowel domain is a total score summed across 3 items and ranges from 0 - 16. The Functional domain score is a total score summed across 3 items and ranges from 0 - 12. A higher CD-PRO/SS score indicates worse quality of life. Participants are included in the analysis if they have both Baseline and at least one post-baseline score available. mITT. Data evaluable participants are included. Results for Induction Phase Cohort 2 and 3 and Maintenance Phase are not presented. Only patients with a baseline score and at least one post-baseline score are included in the analysis.

End point type	Secondary

End point timeframe:

Baseline and Week 14

Notes:

[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: 90% confidence interval was reported for induction phase cohort 1 participants. For induction phase cohort 2 and 3 participants, 95% confidence interval was reported, hence the data is reported as a separate outcome measure for cohort 1. The participants in the maintenance phase were not analyzed for this outcome measure.

End point values	Placebo Cohort 1	Etrolizumab 105mg Cohort 1	Etrolizumab 210mg Cohort 1	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	46	76	87	
Units: score on a scale				
least squares mean (standard error)				

CD-PRO/SS Functional Domain Score	-0.7 (± 0.4)	-1.4 (± 0.3)	-1.6 (± 0.3)	
CD-PRO/SS Bowel Domain Score	-0.7 (± 0.4)	-1.5 (± 0.3)	-1.3 (± 0.3)	

Statistical analyses

No statistical analyses for this end point

Secondary: Induction Phase: Cohort 2 and 3: Change from Baseline in Crohn's Disease-Patient-Reported Outcome Signs and Symptoms (CD-PRO/SS) Score at Week 14

End point title	Induction Phase: Cohort 2 and 3: Change from Baseline in Crohn's Disease-Patient-Reported Outcome Signs and Symptoms (CD-PRO/SS) Score at Week 14[32]

End point description:

CD-PRO/SS: Crohn's Disease Patient Reported Outcomes Signs and Symptoms. For each item, the score is taken as the average across 4-7 days eDiary data within a 9 day window from visit, else the score is considered missing. The CD-PRO/SS Bowel domain is a total score summed across 3 items and ranges from 0 - 16. The Functional domain score is a total score summed across 3 items and ranges from 0 - 12. A higher CD-PRO/SS score indicates worse quality of life. Participants are included in the analysis if they have both Baseline and at least one post-baseline score available. mITT. Data evaluable participants are included. Results for Induction Phase Cohort 1 and Maintenance Phase are not presented. Only patients with a baseline score and at least one post-baseline score are included in the analysis.

End point type	Secondary

End point timeframe:

Baseline and Week 14

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: 90% confidence interval was reported for induction phase cohort 1 participants. For induction phase cohort 2 and 3 participants, 95% confidence interval was reported, hence the data is reported as a separate outcome measure for cohorts 2 and 3. The participants in the maintenance phase were not analyzed for this outcome measure.

End point values	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2	Placebo Cohort 3	Etrolizumab 105mg Cohort 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	132	137	91	138
Units: score on a scale				
least squares mean (standard error)				
CD-PRO/SS Functional Domain Score	-2.0 (± 0.2)	-2.3 (± 0.2)	-1.9 (± 0.3)	-1.6 (± 0.2)
CD-PRO/SS Bowel Domain Score	-2.3 (± 0.3)	-2.2 (± 0.3)	-2.0 (± 0.3)	-2.0 (± 0.3)

End point values	Etrolizumab 210mg Cohort 3			
Subject group type	Reporting group			
Number of subjects analysed	137			
Units: score on a scale				

least squares mean (standard error)				
CD-PRO/SS Functional Domain Score	-1.9 (± 0.2)			
CD-PRO/SS Bowel Domain Score	-2.3 (± 0.3)			

Statistical analyses

Statistical analysis title	Change from Baseline in CD-PRO/SS

Statistical analysis description:

Induction Phase: Change from Baseline in Crohn's Disease-Patient-Reported Outcome Signs and Symptoms (CD-PRO/SS) Score at Week 14

Comparison groups	Placebo Cohort 3 v Etrolizumab 105mg Cohort 3
Number of subjects included in analysis	229
Analysis specification	Pre-specified
Analysis type	superiority[33]
P-value	= 1 [34]
Method	MMRM
Parameter estimate	Difference in LSM
Point estimate	0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.5
upper limit	0.9

Notes:

[33] - Functional Domain Scale

[34] - The multiplicity adjusted p-values are presented.

Statistical analysis title	Change from Baseline in CD-PRO/SS

Statistical analysis description:

Induction Phase: Change from Baseline in Crohn's Disease-Patient-Reported Outcome Signs and Symptoms (CD-PRO/SS) Score at Week 14

Comparison groups	Placebo Cohort 3 v Etrolizumab 210mg Cohort 3
Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority[35]
P-value	= 1 [36]
Method	MMRM
Parameter estimate	Difference in LSM
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.7
upper limit	0.7

Notes:

[35] - Functional Domain Score

[36] - The multiplicity adjusted p-values are presented.

Statistical analysis title	Change from Baseline in CD-PRO/SS

Statistical analysis description:

Induction Phase: Change from Baseline in Crohn's Disease-Patient-Reported Outcome Signs and Symptoms (CD-PRO/SS) Score at Week 14

Comparison groups	Placebo Cohort 3 v Etrolizumab 105mg Cohort 3
Number of subjects included in analysis	229
Analysis specification	Pre-specified
Analysis type	superiority[37]
P-value	= 1 [38]
Method	MMRM
Parameter estimate	Difference in LSM
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8
upper limit	0.9

Notes:

[37] - Bowel Domain Score

[38] - The multiplicity adjusted p-values are presented.

Statistical analysis title	Change from Baseline in CD-PRO/SS

Statistical analysis description:

Induction Phase: Change from Baseline in Crohn's Disease-Patient-Reported Outcome Signs and Symptoms (CD-PRO/SS) Score at Week 14

Comparison groups	Placebo Cohort 3 v Etrolizumab 210mg Cohort 3
Number of subjects included in analysis	228
Analysis specification	Pre-specified
Analysis type	superiority[39]
P-value	= 1 [40]
Method	MMRM
Parameter estimate	Difference in LSM
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.1
upper limit	0.5

Notes:

[39] - Bowel Domain Score

[40] - The multiplicity adjusted p-values are presented.

Secondary: Maintenance Phase: Percentage of Participants with Clinical Remission at Week 66, Among Those who Achieved Clinical Remission at Week 14

End point title	Maintenance Phase: Percentage of Participants with Clinical Remission at Week 66, Among Those who Achieved Clinical Remission at Week 14

End point description:

Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit. mITT. Data evaluable participants are included. Placebo/Placebo Maintenance Cohort is not reported since this is an exploratory population only. Results for Induction Phase is not presented.

End point type	Secondary

End point timeframe:

Baseline, Weeks 14 and 66

End point values	Etrolizumab/Placebo	Etrolizumab/Etrolizumab 105mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	97	108		
Units: percentage of participants				
number (confidence interval 95%)	39.2 (30.05 to 49.12)	56.5 (47.07 to 65.45)		

Statistical analyses

Statistical analysis title	CR at Week 66 subjects achieved CR at Week 14
Statistical analysis description:	
Percentage of Participants with Clinical Remission at Week 66, Among Those who Achieved Clinical Remission at Week 14	
Comparison groups	Etrolizumab/Placebo v Etrolizumab/Etrolizumab 105mg
Number of subjects included in analysis	205
Analysis specification	Pre-specified
Analysis type	superiority[41]
P-value	= 0.0677 [42]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in rate
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.52
upper limit	30.27

Notes:

[41] - Difference in remission rates is adjusted using CMH weights and the 95% CIs use the Newcombes method.
[42] - The multiplicity adjusted p-values are presented.

Secondary: Maintenance Phase: Percentage of Participants with Corticosteroid-Free Clinical Remission at Week 66, Among Those who Were Receiving Corticosteroids at Baseline

End point title	Maintenance Phase: Percentage of Participants with Corticosteroid-Free Clinical Remission at Week 66, Among Those who Were Receiving Corticosteroids at Baseline
End point description:	
Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit. mITT. Maintenance Phase Cohorts only. Placebo/Placebo Maintenance Cohort is not reported since this is an exploratory population only. Only patients receiving oral corticosteroids at Baseline are included in the analysis.	
End point type	Secondary
End point timeframe:	
Baseline and Week 66	

End point values	Etrolizumab/Placebo	Etrolizumab/Etrolizumab 105mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	91	93		
Units: percentage of participants				
number (confidence interval 95%)	11.0 (6.08 to 19.06)	29.0 (20.79 to 38.94)		

Statistical analyses

Statistical analysis title	Participants with Corticosteroid-Free CR Week 66

Statistical analysis description:

Maintenance Phase: Percentage of Participants with Corticosteroid-Free Clinical Remission at Week 66, Among Those who Were Receiving Corticosteroids at Baseline

Comparison groups	Etrolizumab/Placebo v Etrolizumab/Etrolizumab 105mg
Number of subjects included in analysis	184
Analysis specification	Pre-specified
Analysis type	superiority[43]
P-value	= 0.048 [44]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in rates
Point estimate	18.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	11.07
upper limit	25.96

Notes:

[43] - Difference in remission rates is adjusted using CMH weights and the 95% CIs use the Newcombes method.
[44] - The multiplicity adjusted p-values are presented.

Secondary: Maintenance Phase: Percentage of Participants with Endoscopic Improvement at Week 66 Among Participants who Achieved Endoscopic Improvement at Week 14

End point title	Maintenance Phase: Percentage of Participants with Endoscopic Improvement at Week 66 Among Participants who Achieved Endoscopic Improvement at Week 14

End point description:

Endoscopic improvement is defined as 50% reduction from baseline in SES-CD score. mITT. Only patients achieving endoscopic improvement at Week 14 are included in the analysis. Results for Induction Phase Cohort is not presented.

End point type	Secondary

End point timeframe:

Baseline, Weeks 14 and 66

End point values	Etrolizumab/Placebo	Etrolizumab/Etrolizumab 105mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	58	72		
Units: percentage of participants				
number (confidence interval 95%)	25.3 (14.14 to 36.44)	37.5 (26.28 to 48.72)		

Statistical analyses

Statistical analysis title	Subjects with Endoscopic Improvement Week 66

Statistical analysis description:

Etrolizumab/Placebo vs. Etrolizumab/Etrolizumab 105mg. Only patients achieving endoscopic Improvement at Week 14 are included in the analysis.

Comparison groups	Etrolizumab/Placebo v Etrolizumab/Etrolizumab 105mg
Number of subjects included in analysis	130
Analysis specification	Pre-specified
Analysis type	superiority[45]
P-value	= 0.121
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in rates
Point estimate	13.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.9
upper limit	29.94

Notes:

[45] - Difference in response rates is adjusted using CMH weights and the 95% CIs use the Newcombes method.

Secondary: Maintenance Phase: Percentage of Participants with SES-CD Score ≤4 (≤2 for Ileal Participants), with No Segment Having a Subcategory Score >1, at Week 66

End point title	Maintenance Phase: Percentage of Participants with SES-CD Score ≤4 (≤2 for Ileal Participants), with No Segment Having a Subcategory Score >1, at Week 66

End point description:

Endoscopic Remission is defined as SES-CD total score <=4 (<=2 for ileal only patients), with no segment having a subcategory score >1. SES-CD = Simple Endoscopic Score for Crohn's Disease. A composite of four assessments, each rated from 0 to 3: size of ulcers, proportion of the surface covered by ulcers, proportion of the surface with any other lesions, and presence of narrowings (stenosis). The SES-CD total score ranges from 0 to 60, a higher score indicates worse disease activity. mITT. Maintenance Phase Placebo/Placebo is not reported since this is an exploratory population only.

End point type	Secondary

End point timeframe:

Week 66

End point values	Etrolizumab/Placebo	Etrolizumab/Etrolizumab 105mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	217	217		
Units: percentage of participants				
number (confidence interval 95%)	5.9 (2.62 to 9.18)	12.1 (7.61 to 16.54)		

Statistical analyses

Statistical analysis title	Participants with SES-CD Score ≤4

Statistical analysis description:

Maintenance Phase: Percentage of Participants with SES-CD Score ≤4 (≤2 for Ileal Participants), with No Segment Having a Subcategory Score >1, at Week 66

Comparison groups	Etrolizumab/Placebo v Etrolizumab/Etrolizumab 105mg
Number of subjects included in analysis	434
Analysis specification	Pre-specified
Analysis type	superiority[46]
P-value	= 0.048 [47]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in rates
Point estimate	6.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.54
upper limit	11.93

Notes:

[46] - Difference in remission rates is adjusted using CMH weights and the 95% CIs use the Newcombes method.
[47] - The multiplicity adjusted p-values are presented.

Secondary: Maintenance Phase: Percentage of Participants with Durable Clinical Remission

End point title	Maintenance Phase: Percentage of Participants with Durable Clinical Remission

End point description:

Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit. Durable clinical remission was defined as clinical remission at ≥4 of the 6 in-clinic assessment visits conducted during the Maintenance Phase at Weeks 24, 28, 32, 44, 56, and 66. mITT. Maintenance Phase Placebo/Placebo arm is not reported since this is an exploratory population only. Results for Induction Phase is not presented.

End point type	Secondary

End point timeframe:

Week 14 up to Week 66 (assessed at Weeks 24, 28, 32, 44, 56, and 66)

End point values	Etrolizumab/Placebo	Etrolizumab/Etrolizumab 105mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	217	217		
Units: percentage of participants				
number (confidence interval 95%)	19.8 (15.06 to 25.62)	30.9 (25.11 to 37.31)		

Statistical analyses

Statistical analysis title	Participants with Durable CR
Statistical analysis description:	
Maintenance Phase: Percentage of Participants with Durable Clinical Remission (CR)	
Comparison groups	Etrolizumab/Placebo v Etrolizumab/Etrolizumab 105mg
Number of subjects included in analysis	434
Analysis specification	Pre-specified
Analysis type	superiority[48]
P-value	= 0.0677 [49]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in rates
Point estimate	11.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.04
upper limit	19.24

Notes:

[48] - Difference in response rates is adjusted using CMH weights and the 95% CIs use the Newcombes method.

[49] - The multiplicity adjusted p-values are presented.

Secondary: Maintenance Phase: Percentage of Participants with Corticosteroid-Free Clinical Remission for at Least 24 Weeks at Week 66, Among Those who Were Receiving Corticosteroids at Baseline

End point title	Maintenance Phase: Percentage of Participants with Corticosteroid-Free Clinical Remission for at Least 24 Weeks at Week 66, Among Those who Were Receiving Corticosteroids at Baseline

End point description:

Clinical remission is defined as SF mean daily score ≤3 and abdominal pain mean daily score ≤1, with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit. Percentage of participants with clinical remission who will be off corticosteroids for at least 24 weeks prior to Week 66 will be reported. mITT. Maintenance Phase Placebo/Placebo is arm is not reported since this is an exploratory population only. Results for Induction Phase is not presented. Only patients receiving oral corticosteroids at Baseline are included in the analysis.

End point type	Secondary

End point timeframe:

Baseline and from Week 14 up to Week 66

End point values	Etrolizumab/Placebo	Etrolizumab/Etrolizumab 105mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	91	93		
Units: percentage of participants				
number (confidence interval 95%)	9.9 (5.29 to 17.74)	25.8 (18.00 to 35.53)		

Statistical analyses

Statistical analysis title	Participants with Corticosteroid-Free CR Week 66

Statistical analysis description:

Maintenance Phase: Percentage of Participants with Corticosteroid-Free Clinical Remission for at Least 24 Weeks at Week 66, Among Those who Were Receiving Corticosteroids at Baseline

Comparison groups	Etrolizumab/Placebo v Etrolizumab/Etrolizumab 105mg
Number of subjects included in analysis	184
Analysis specification	Pre-specified
Analysis type	superiority[50]
P-value	= 0.0035 [51]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in rates
Point estimate	16.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.96
upper limit	23.31

Notes:

[50] - Difference in remission rates is adjusted using CMH weights and the 95% CIs use the Newcombes method.
[51] - Nominal p-values are presented. No adjustment for multiplicity

Secondary: Maintenance Phase: Change from Baseline in CD-PRO/SS Score at Week 66

End point title	Maintenance Phase: Change from Baseline in CD-PRO/SS Score at Week 66

End point description:

CD-PRO/SS: Crohn's Disease Patient Reported Outcomes Signs and Symptoms. For each item, the score is taken as the average across 4-7 days eDiary data within a 9 day window from visit, else the score is considered missing. The CD-PRO/SS Bowel domain is a total score summed across 3 items and ranges from 0 - 16. The Functional domain score is a total score summed across 3 items and ranges from 0 - 12. A higher CD-PRO/SS score indicates worse quality of life. Participants are included in the analysis if they have both Baseline and at least one post-baseline score available. mITT. Data evaluable participants are included. Only patients with a baseline score and at least one post-baseline score are included in the analysis. The Maintenance Phase Placebo/Placebo arm is not reported since this is an exploratory population only. Results for Induction Phase is not presented.

End point type	Secondary

End point timeframe:

Baseline and Week 66

End point values	Etrolizumab/Placebo	Etrolizumab/Etrolizumab 105mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	180		
Units: score on a scale				
least squares mean (standard error)				
Bowel	-1.7 (± 0.3)	-2.0 (± 0.3)		
Functional	-1.4 (± 0.2)	-1.7 (± 0.2)		

Statistical analyses

Statistical analysis title	Change from Baseline in CD-PRO/SS Score Week 66
Statistical analysis description:	
Maintenance Phase: Change from Baseline in CD-PRO/SS Score at Week 66	
Comparison groups	Etrolizumab/Placebo v Etrolizumab/Etrolizumab 105mg
Number of subjects included in analysis	360
Analysis specification	Pre-specified
Analysis type	superiority[52]
P-value	= 0.4009 [53]
Method	MMRM
Parameter estimate	Difference in LSM
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.9
upper limit	0.4

Notes:

[52] - Functional Symptoms Domain

[53] - The multiplicity adjusted p-values are presented.

Statistical analysis title	Change from Baseline in CD-PRO/SS Score at Week 66
Statistical analysis description:	
Maintenance Phase: Change from Baseline in CD-PRO/SS Score at Week 66	
Comparison groups	Etrolizumab/Placebo v Etrolizumab/Etrolizumab 105mg
Number of subjects included in analysis	360
Analysis specification	Pre-specified
Analysis type	superiority[54]
P-value	= 0.4009 [55]
Method	MMRM
Parameter estimate	Difference in LSM
Point estimate	-0.3

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	0.4

Notes:

[54] - Bowel Symptoms Domain

[55] - The multiplicity adjusted p-values are presented.

Secondary: Overall Number of Participants who Experienced at Least One Adverse Event by Severity, According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)

End point title	Overall Number of Participants who Experienced at Least One Adverse Event by Severity, According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)

End point description:

Investigator text for AEs is coded using MedDRA version 24.0. For participants counts, multiple occurrences of AEs in the same category for an individual are counted only once. For event counts, multiple occurrences of AEs in the same category for an individual are counted separately. Severity Grades from 1 to 5. Safety Population.

End point type	Secondary

End point timeframe:

From Baseline up to Week 78

End point values	Placebo Cohort 1	Placebo/Placebo	Etrolizumab 105mg Cohort 1	Etrolizumab/Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59[56]	53[57]	120[58]	217[59]
Units: Number of Participants				
number (not applicable)	50	42	83	190

Notes:

[56] - data evaluable participants are included in each Grade group

[57] - data evaluable participants are included in each Grade group

[58] - data evaluable participants are included in each Grade group

[59] - data evaluable participants are included in each Grade group

End point values	Etrolizumab 210mg Cohort 1	Etrolizumab/Etrolizumab 105mg	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	121[60]	217[61]	176[62]	174[63]
Units: Number of Participants				
number (not applicable)	82	189	120	115

Notes:

[60] - data evaluable participants are included in each Grade group

[61] - data evaluable participants are included in each Grade group

[62] - data evaluable participants are included in each Grade group

[63] - data evaluable participants are included in each Grade group

End point values	Placebo Cohort 3	Etrolizumab 105mg Cohort	Etrolizumab 210mg Cohort	

		3	3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	96[64]	143[65]	145[66]	
Units: Number of Participants				
number (not applicable)	51	95	85	

Notes:

[64] - data evaluable participants are included in each Grade group

[65] - data evaluable participants are included in each Grade group

[66] - data evaluable participants are included in each Grade group

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Number of Participants with Adverse Events Leading to Study Drug Discontinuation

End point title	Overall Number of Participants with Adverse Events Leading to Study Drug Discontinuation

End point description:

Number of participants who discontinued the study due to the adverse events is reported. Safety Population.

End point type	Secondary

End point timeframe:

From Baseline up to Week 78

End point values	Placebo Cohort 1	Placebo/Placebo	Etrolizumab 105mg Cohort 1	Etrolizumab/Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59[67]	53[68]	120[69]	217[70]
Units: Number of Participants				
number (not applicable)	2	1	4	1

Notes:

[67] - data evaluable participants are included in each Grade group

[68] - data evaluable participants are included in each Grade group

[69] - data evaluable participants are included in each Grade group

[70] - data evaluable participants are included in each Grade group

End point values	Etrolizumab 210mg Cohort 1	Etrolizumab/Etrolizumab 105mg	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	121[71]	217[72]	176[73]	174[74]
Units: Number of Participants				
number (not applicable)	1	3	2	5

Notes:

[71] - data evaluable participants are included in each Grade group

[72] - data evaluable participants are included in each Grade group

[73] - data evaluable participants are included in each Grade group

[74] - data evaluable participants are included in each Grade group

End point values	Placebo Cohort 3	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	96[75]	143[76]	145[77]	
Units: Number of Participants				
number (not applicable)	2	0	0	

Notes:

[75] - data evaluable participants are included in each Grade group

[76] - data evaluable participants are included in each Grade group

[77] - data evaluable participants are included in each Grade group

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Number of Participants who Experienced at Least One Infection-Related Adverse Event by Severity, According to NCI-CTCAE v4.0

End point title	Overall Number of Participants who Experienced at Least One Infection-Related Adverse Event by Severity, According to NCI-CTCAE v4.0

End point description:

Participants who Experienced at Least One Infection-Related Adverse Event by Severity, According to NCI-CTCAE v4.0 are reported. Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = Death. Safety Population.

End point type	Secondary

End point timeframe:

From Baseline up to Week 78

End point values	Placebo Cohort 1	Placebo/Placebo	Etrolizumab 105mg Cohort 1	Etrolizumab/Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59[78]	53[79]	120[80]	217[81]
Units: Number of Participants				
number (not applicable)				
Grade 1 (n=11,30,32,66,50,16,40,42,22,121,10	8	9	10	44
Grade 2 (n=11,30,32,66,50,16,40,42,22,121,10	2	11	17	65
Grade 3 (n=11,30,32,66,50,16,40,42,22,121,10	1	2	2	11
Grade 4 (n=11,30,32,66,50,16,40,42,22,121,10	0	0	1	1
Grade 5 (n=11,30,32,66,50,16,40,42,22,121,10	0	0	0	0

Notes:

[78] - data evaluable participants are included in each Grade group

[79] - data evaluable participants are included in each Grade group

[80] - data evaluable participants are included in each Grade group

[81] - data evaluable participants are included in each Grade group

End point values	Etrolizumab 210mg Cohort 1	Etrolizumab/Etrolizumab 105mg	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	121[82]	217[83]	176[84]	174[85]
Units: Number of Participants				
number (not applicable)				
Grade 1 (n=11,30,32,66,50,16,40,42,22,121,10	16	42	38	21
Grade 2 (n=11,30,32,66,50,16,40,42,22,121,10	24	53	23	20
Grade 3 (n=11,30,32,66,50,16,40,42,22,121,10	2	10	5	8
Grade 4 (n=11,30,32,66,50,16,40,42,22,121,10	0	0	0	1
Grade 5 (n=11,30,32,66,50,16,40,42,22,121,10	0	1	0	0

Notes:

[82] - data evaluable participants are included in each Grade group

[83] - data evaluable participants are included in each Grade group

[84] - data evaluable participants are included in each Grade group

[85] - data evaluable participants are included in each Grade group

End point values	Placebo Cohort 3	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	96[86]	143[87]	145[88]	
Units: Number of Participants				
number (not applicable)				
Grade 1 (n=11,30,32,66,50,16,40,42,22,121,10	8	25	21	
Grade 2 (n=11,30,32,66,50,16,40,42,22,121,10	7	12	20	
Grade 3 (n=11,30,32,66,50,16,40,42,22,121,10	1	2	1	
Grade 4 (n=11,30,32,66,50,16,40,42,22,121,10	0	1	0	
Grade 5 (n=11,30,32,66,50,16,40,42,22,121,10	0	0	0	

Notes:

[86] - data evaluable participants are included in each Grade group

[87] - data evaluable participants are included in each Grade group

[88] - data evaluable participants are included in each Grade group

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Number of Participants who Experienced at Least One Infection-Related Serious Adverse Event

End point title	Overall Number of Participants who Experienced at Least One Infection-Related Serious Adverse Event

End point description:	
Safety Population	
End point type	Secondary
End point timeframe:	
From Baseline up to Week 78	

End point values	Placebo Cohort 1	Placebo/Placebo	Etrolizumab 105mg Cohort 1	Etrolizumab/Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59[89]	53[90]	120[91]	217[92]
Units: Number of Participants				
number (not applicable)	2	1	4	13

Notes:

[89] - data evaluable participants are included in each Grade group

[90] - data evaluable participants are included in each Grade group

[91] - data evaluable participants are included in each Grade group

[92] - data evaluable participants are included in each Grade group

End point values	Etrolizumab 210mg Cohort 1	Etrolizumab/Etrolizumab 105mg	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	121[93]	217[94]	176[95]	174[96]
Units: Number of Participants				
number (not applicable)	1	12	2	5

Notes:

[93] - data evaluable participants are included in each Grade group

[94] - data evaluable participants are included in each Grade group

[95] - data evaluable participants are included in each Grade group

[96] - data evaluable participants are included in each Grade group

End point values	Placebo Cohort 3	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	96[97]	143[98]	145[99]	
Units: Number of Participants				
number (not applicable)	1	2	2	

Notes:

[97] - data evaluable participants are included in each Grade group

[98] - data evaluable participants are included in each Grade group

[99] - data evaluable participants are included in each Grade group

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Number of Participants who Experienced at Least One Injection-Site Reaction by Severity, According to NCI-CTCAE v4.0

End point title	Overall Number of Participants who Experienced at Least One Injection-Site Reaction by Severity, According to NCI-CTCAE

	v4.0

End point description:

Investigator test for AEs is coding using MedDRA version 24.0. Injection-Site Reactions are identified by eCRF checkbox for local injection site reactions, and/or primary or secondary HLT Injection Site Reactions. Multiple occurrences of AEs for an individual are counted only once, under the worst grade reported. Safety Population. Result data evaluable participants are included.

End point type	Secondary

End point timeframe:

From Baseline up to Week 78

End point values	Placebo Cohort 1	Placebo/Placebo	Etrolizumab 105mg Cohort 1	Etrolizumab/Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59[100]	53[101]	120[102]	217[103]
Units: Number of Participants				
number (not applicable)				
Grade 1 (n=4,7,4,10,9,1,11,6,3,18,9)	4	3	7	18
Grade 2 (n=4,7,4,10,9,1,11,6,3,18,9)	0	0	0	0
Grade 3 (n=4,7,4,10,9,1,11,6,3,18,9)	0	0	0	0
Grade 4 (n=4,7,4,10,9,1,11,6,3,18,9)	0	0	0	0
Grade 5 (n=4,7,4,10,9,1,11,6,3,18,9)	0	0	0	0

Notes:

[100] - data evaluable participants are included in each Grade group

[101] - data evaluable participants are included in each Grade group

[102] - data evaluable participants are included in each Grade group

[103] - data evaluable participants are included in each Grade group

End point values	Etrolizumab 210mg Cohort 1	Etrolizumab/Etrolizumab 105mg	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	121[104]	217[105]	176[106]	174[107]
Units: Number of Participants				
number (not applicable)				
Grade 1 (n=4,7,4,10,9,1,11,6,3,18,9)	3	8	10	8
Grade 2 (n=4,7,4,10,9,1,11,6,3,18,9)	1	1	0	1
Grade 3 (n=4,7,4,10,9,1,11,6,3,18,9)	0	0	0	0
Grade 4 (n=4,7,4,10,9,1,11,6,3,18,9)	0	0	0	0
Grade 5 (n=4,7,4,10,9,1,11,6,3,18,9)	0	0	0	0

Notes:

[104] - data evaluable participants are included in each Grade group

[105] - data evaluable participants are included in each Grade group

[106] - data evaluable participants are included in each Grade group

[107] - data evaluable participants are included in each Grade group

End point values	Placebo Cohort 3	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	96[108]	143[109]	145[110]	
Units: Number of Participants				

number (not applicable)				
Grade 1 (n=4,7,4,10,9,1,11,6,3,18,9)	1	10	6	
Grade 2 (n=4,7,4,10,9,1,11,6,3,18,9)	0	1	0	
Grade 3 (n=4,7,4,10,9,1,11,6,3,18,9)	0	0	0	
Grade 4 (n=4,7,4,10,9,1,11,6,3,18,9)	0	0	0	
Grade 5 (n=4,7,4,10,9,1,11,6,3,18,9)	0	0	0	

Notes:

[108] - data evaluable participants are included in each Grade group

[109] - data evaluable participants are included in each Grade group

[110] - data evaluable participants are included in each Grade group

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Number of Participants who Experienced at Least One Hypersensitivity Reaction by Severity, According to NCI-CTCAE v4.0

End point title	Overall Number of Participants who Experienced at Least One Hypersensitivity Reaction by Severity, According to NCI-CTCAE v4.0

End point description:

Investigator text for AEs is coded using MedDRA version 24.0. Multiple occurrences of AEs for an individual are counted only once, under the worst grade reported. Safety Population. Result data evaluable participants are included.

End point type	Secondary

End point timeframe:

From Baseline up to Week 78

End point values	Placebo Cohort 1	Placebo/Placebo	Etrolizumab 105mg Cohort 1	Etrolizumab/Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59[111]	53[112]	120[113]	217[114]
Units: Number of Participants				
number (not applicable)				
Grade 1	0	0	0	0
Grade 2	2	0	1	0
Grade 3	0	0	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0

Notes:

[111] - data evaluable participants are included in each Grade group

[112] - data evaluable participants are included in each Grade group

[113] - data evaluable participants are included in each Grade group

[114] - data evaluable participants are included in each Grade group

End point values	Etrolizumab 210mg Cohort 1	Etrolizumab/Etrolizumab 105mg	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	121[115]	217[116]	176[117]	174[118]
Units: Number of Participants				

number (not applicable)				
Grade 1	0	0	0	0
Grade 2	1	0	0	0
Grade 3	0	0	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0

Notes:

[115] - data evaluable participants are included in each Grade group

[116] - data evaluable participants are included in each Grade group

[117] - data evaluable participants are included in each Grade group

[118] - data evaluable participants are included in each Grade group

End point values	Placebo Cohort 3	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	96[119]	143[120]	145[121]	
Units: Number of Participants				
number (not applicable)				
Grade 1	0	1	0	
Grade 2	0	0	0	
Grade 3	0	0	0	
Grade 4	0	0	0	
Grade 5	0	0	0	

Notes:

[119] - data evaluable participants are included in each Grade group

[120] - data evaluable participants are included in each Grade group

[121] - data evaluable participants are included in each Grade group

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Number of Participants who Develop Malignancies

End point title	Overall Number of Participants who Develop Malignancies

End point description:

Participants with malignancies are reported. Malignancies are identified by SMQ Malignant and unspecified tumors (narrow). Safety Population.

End point type	Secondary

End point timeframe:

From Baseline up to Week 78

End point values	Placebo Cohort 1	Placebo/Placebo	Etrolizumab 105mg Cohort 1	Etrolizumab/Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59[122]	53[123]	120[124]	217[125]
Units: Number of Participants				
number (not applicable)	0	0	1	2

Notes:

[122] - data evaluable participants are included in each Grade group

[123] - data evaluable participants are included in each Grade group

[124] - data evaluable participants are included in each Grade group

[125] - data evaluable participants are included in each Grade group

End point values	Etrolizumab 210mg Cohort 1	Etrolizumab/Etrolizumab 105mg	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	121[126]	217[127]	176[128]	174[129]
Units: Number of Participants				
number (not applicable)	1	1	0	1

Notes:

[126] - data evaluable participants are included in each Grade group

[127] - data evaluable participants are included in each Grade group

[128] - data evaluable participants are included in each Grade group

[129] - data evaluable participants are included in each Grade group

End point values	Placebo Cohort 3	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	96[130]	143[131]	145[132]	
Units: Number of Participants				
number (not applicable)	0	0	0	

Notes:

[130] - data evaluable participants are included in each Grade group

[131] - data evaluable participants are included in each Grade group

[132] - data evaluable participants are included in each Grade group

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Etrolizumab

End point title	Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Etrolizumab

End point description:

Participants who received at least one dose of study treatment and had at least one baseline or post-baseline ATA result. Induction: treatment groups were pooled across cohorts 1-3. Maintenance: treatment group is stratified by induction dose

End point type	Secondary

End point timeframe:

Baseline, Pre-dose (Hour 0) on Weeks 4, 14, 24, 32, 44, 66 or early termination, 12 weeks after last dose (up to Week 78)

End point values	Etro 105mg Induction Only Cohort	Etro 210mg Induction Only Cohort	Etro 105/ Placebo Induction and Maintenance Phase Cohort	Etro 210/ Placebo Induction and Maintenance Phase
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	222[133]	223[134]	108[135]	109[136]
Units: Percentage of participants				
number (not applicable)				
Baseline (positive ADA) n=217,218,107,108,107,108	4.1	2.8	2.8	5.6
Treatment emergent ADA n=213,216,108,109,109,108	23	22.7	23.1	33.9

Notes:

[133] - Data evaluable participants are included in each group

[134] - Data evaluable participants are included in each group

[135] - Data evaluable participants are included in each group

[136] - Data evaluable participants are included in each group

End point values	Etro 105/Etro 105 Induction and Maintenance Phase	Etro 210/Etro 105 Induction and Maintenance Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	109[137]	108[138]		
Units: Percentage of participants				
number (not applicable)				
Baseline (positive ADA) n=217,218,107,108,107,108	2.8	0		
Treatment emergent ADA n=213,216,108,109,109,108	33.9	21.3		

Notes:

[137] - Data evaluable participants are included in each group

[138] - Data evaluable participants are included in each group

Statistical analyses

No statistical analyses for this end point

Secondary: Observed Trough Serum Concentration (Ctrough) of Etrolizumab

End point title	Observed Trough Serum Concentration (Ctrough) of Etrolizumab[139]

End point description:

Serum etrolizumab trough concentration. mITT. All participants who received at least one dose of study drug and had evaluable PK data.

End point type	Secondary

End point timeframe:

Induction Phase at Weeks 10 and 14, Maintenance Phase at Weeks 16, 24, 28, 32, 44, and 66

Notes:

[139] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Serum etrolizumab trough concentration was analyzed.

End point values	Etrolizumab 105mg Cohort 1	Etrolizumab 210mg Cohort 1	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	117[140]	121[141]	175[142]	172[143]
Units: microgram/mL				
arithmetic mean (standard deviation)				
Week 10 (n=104, 112,158,160,124,126,0,0)	9.39 (± 4.59)	25.1 (± 11.6)	10.3 (± 5.07)	25.7 (± 11.9)
Week 14 (n=96, 103, 148,144,115,120,0,0)	10.2 (± 5.27)	23.2 (± 10.6)	11.0 (± 5.04)	24.1 (± 11.4)
Week 16 (n=0,0,0,0,0,0,102,94)	0 (± 0)	0 (± 0)	0 (± 0)	0 (± 0)
Week 24 (n=0,0,0,0,0,0,96,97)	0 (± 0)	0 (± 0)	0 (± 0)	0 (± 0)
Week 28 (n=0,0,0,0,0,0,88,82)	0 (± 0)	0 (± 0)	0 (± 0)	0 (± 0)
Week 32 (n=0,0,0,0,0,0,85,81)	0 (± 0)	0 (± 0)	0 (± 0)	0 (± 0)
Week 44 (n=0,0,0,0,0,0,68, 73)	0 (± 0)	0 (± 0)	0 (± 0)	0 (± 0)
Week 66 (n=0,0,0,0,0,0,61,63)	0 (± 0)	0 (± 0)	0 (± 0)	0 (± 0)

Notes:

[140] - Data evaluable participants are included in each cohort

[141] - Data evaluable participants are included in each cohort

[142] - Data evaluable participants are included in each cohort

[143] - Data evaluable participants are included in each cohort

End point values	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3	Maintenance Phase - Etrolizumab 105 mg/ Etrolizumab 105 mg	Maintenance Phase - Etrolizumab 210 mg/ Etrolizumab 105 mg
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	138[144]	141[145]	109[146]	108[147]
Units: microgram/mL				
arithmetic mean (standard deviation)				
Week 10 (n=104, 112,158,160,124,126,0,0)	9.78 (± 4.63)	25.5 (± 11.0)	0 (± 0)	0 (± 0)
Week 14 (n=96, 103, 148,144,115,120,0,0)	10.8 (± 5.43)	24.6 (± 9.53)	0 (± 0)	0 (± 0)
Week 16 (n=0,0,0,0,0,0,102,94)	0 (± 0)	0 (± 0)	6.15 (± 4.20)	14.8 (± 10.5)
Week 24 (n=0,0,0,0,0,0,96,97)	0 (± 0)	0 (± 0)	6.58 (± 4.59)	8.20 (± 6.34)
Week 28 (n=0,0,0,0,0,0,88,82)	0 (± 0)	0 (± 0)	7.29 (± 8.45)	8.07 (± 5.81)
Week 32 (n=0,0,0,0,0,0,85,81)	0 (± 0)	0 (± 0)	7.13 (± 9.76)	7.89 (± 5.96)
Week 44 (n=0,0,0,0,0,0,68, 73)	0 (± 0)	0 (± 0)	6.68 (± 3.75)	8.31 (± 6.68)
Week 66 (n=0,0,0,0,0,0,61,63)	0 (± 0)	0 (± 0)	11.7 (± 5.82)	12.2 (± 6.44)

Notes:

[144] - Data evaluable participants are included in each cohort

[145] - Data evaluable participants are included in each cohort

[146] - Data evaluable participants are included in each cohort

[147] - Data evaluable participants are included in each cohort

Statistical analyses

No statistical analyses for this end point

Adverse events information

Timeframe for reporting adverse events:

From Baseline up to a maximum of 78 weeks

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	24.0

Reporting groups

Reporting group title	Etrolizumab 105mg Cohort 1

Reporting group description:

Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Placebo Cohort 1

Reporting group description:

Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.

Reporting group title	Etrolizumab 105mg Cohort 2

Reporting group description:

Cohort 2 is enrolling participants after Cohort 1 and is considered a "feeder" cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Etrolizumab 210mg Cohort 1

Reporting group description:

Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one subcutaneous (SC) injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Etrolizumab 210mg Cohort 2

Reporting group description:

Cohort 2 is enrolling participants after Cohort 1 and is considered a "feeder" cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking for the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Etrolizumab/Placebo

Reporting group description:

Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of placebo q4w from Week 16 to Week 64

Reporting group title	Placebo/Placebo

Reporting group description:

Participants who received placebo during the Induction Phase (from Cohorts 1 and 3) and achieved a CDAI-70 response at Week 14 will undergo a sham randomization into the Maintenance Phase. Placebo responders from induction will receive blinded maintenance treatment with an SC injection of placebo once every 4 weeks (q4w) from Week 16 to Week 64.

Reporting group title	Etrolizumab 105mg Cohort 3

Reporting group description:

Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Etrolizumab 210mg Cohort 3

Reporting group description:

Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Placebo Cohort 3

Reporting group description:

Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.

Reporting group title	Etrolizumab/Etrolizumab 105mg

Reporting group description:

Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of etrolizumab (105 mg) q4w from Week 16 to Week 64.

Serious adverse events	Etrolizumab 105mg Cohort 1	Placebo Cohort 1	Etrolizumab 105mg Cohort 2
Total subjects affected by serious adverse events			
subjects affected / exposed	20 / 120 (16.67%)	8 / 59 (13.56%)	18 / 176 (10.23%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma pancreas			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral embolism			

subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Removal of foreign body from gastrointestinal tract			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Granuloma			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Female genital tract fistula			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic pain			

subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax spontaneous			
subjects affected / exposed	1 / 120 (0.83%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 120 (0.00%)	1 / 59 (1.69%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatinine increased			
subjects affected / exposed	1 / 120 (0.83%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver function test abnormal			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Gastrointestinal anastomotic leak			
subjects affected / exposed	1 / 120 (0.83%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural intestinal perforation			

subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thermal burn			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral gas embolism			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tremor			
subjects affected / exposed	1 / 120 (0.83%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 120 (0.00%)	1 / 59 (1.69%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			

Acute vestibular syndrome			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertigo positional			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Optic neuropathy			
subjects affected / exposed	1 / 120 (0.83%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 120 (0.00%)	1 / 59 (1.69%)	2 / 176 (1.14%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Crohn's disease			
subjects affected / exposed	12 / 120 (10.00%)	6 / 59 (10.17%)	5 / 176 (2.84%)
occurrences causally related to treatment / all	0 / 12	0 / 9	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Colitis			
subjects affected / exposed	1 / 120 (0.83%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocutaneous fistula			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovesical fistula			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer haemorrhage			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileal stenosis			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	1 / 120 (0.83%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			

subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal fistula			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mechanical ileus			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctitis			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	1 / 120 (0.83%)	0 / 59 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal perforation			

subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Acute febrile neutrophilic dermatosis			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema nodosum			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Excessive granulation tissue			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scar pain			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Chronic kidney disease			
subjects affected / exposed	1 / 120 (0.83%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Nephrolithiasis			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			
subjects affected / exposed	1 / 120 (0.83%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 120 (0.00%)	1 / 59 (1.69%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myositis			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal abscess			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Abdominal wall abscess			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess intestinal			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asymptomatic COVID-19			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 120 (0.83%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			

subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 120 (0.00%)	1 / 59 (1.69%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis listeria			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pilonidal cyst			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			

subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal abscess			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	1 / 120 (0.83%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrolyte imbalance			

subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 120 (0.00%)	0 / 59 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Etrolizumab 210mg Cohort 1	Etrolizumab 210mg Cohort 2	Etrolizumab/Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	12 / 121 (9.92%)	20 / 174 (11.49%)	33 / 217 (15.21%)
number of deaths (all causes)	0	1	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma pancreas			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral embolism			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Removal of foreign body from gastrointestinal tract			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			

subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Granuloma			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Female genital tract fistula			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	2 / 217 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic pain			
subjects affected / exposed	1 / 121 (0.83%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax spontaneous			

subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatinine increased			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver function test abnormal			
subjects affected / exposed	1 / 121 (0.83%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Gastrointestinal anastomotic leak			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural intestinal perforation			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thermal burn			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Nervous system disorders			
Headache			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral gas embolism			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tremor			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 121 (0.83%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Acute vestibular syndrome			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertigo positional			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Optic neuropathy			

subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	2 / 121 (1.65%)	2 / 174 (1.15%)	2 / 217 (0.92%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Crohn's disease			
subjects affected / exposed	7 / 121 (5.79%)	10 / 174 (5.75%)	14 / 217 (6.45%)
occurrences causally related to treatment / all	0 / 7	0 / 11	0 / 15
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocutaneous fistula			

subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovesical fistula			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer haemorrhage			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileal stenosis			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal fistula			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			

subjects affected / exposed	0 / 121 (0.00%)	2 / 174 (1.15%)	2 / 217 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mechanical ileus			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctitis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal perforation			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholelithiasis			

subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Acute febrile neutrophilic dermatosis			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema nodosum			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Excessive granulation tissue			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scar pain			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Chronic kidney disease			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			

subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myositis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal abscess			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall abscess			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess intestinal			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Anal abscess			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asymptomatic COVID-19			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	1 / 121 (0.83%)	1 / 174 (0.57%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			

subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis listeria			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pilonidal cyst			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal abscess			
subjects affected / exposed	1 / 121 (0.83%)	2 / 174 (1.15%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			

subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 217 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrolyte imbalance			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 217 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Placebo/Placebo	Etrolizumab 105mg	Etrolizumab 210mg

		Cohort 3	Cohort 3
Total subjects affected by serious adverse events			
subjects affected / exposed	9 / 53 (16.98%)	12 / 143 (8.39%)	8 / 145 (5.52%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma pancreas			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral embolism			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Removal of foreign body from gastrointestinal tract			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Granuloma			

subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Female genital tract fistula			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic pain			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax spontaneous			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatinine increased			

subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver function test abnormal			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Gastrointestinal anastomotic leak			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural intestinal perforation			
subjects affected / exposed	0 / 53 (0.00%)	1 / 143 (0.70%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thermal burn			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral gas embolism			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Tremor			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 53 (1.89%)	2 / 143 (1.40%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 53 (0.00%)	1 / 143 (0.70%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Acute vestibular syndrome			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertigo positional			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Optic neuropathy			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	2 / 145 (1.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Crohn's disease			

subjects affected / exposed	4 / 53 (7.55%)	7 / 143 (4.90%)	5 / 145 (3.45%)
occurrences causally related to treatment / all	0 / 4	0 / 8	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocutaneous fistula			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovesical fistula			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer haemorrhage			

subjects affected / exposed	1 / 53 (1.89%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileal stenosis			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal fistula			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	1 / 53 (1.89%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mechanical ileus			

subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctitis			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	1 / 145 (0.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal perforation			
subjects affected / exposed	1 / 53 (1.89%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Acute febrile neutrophilic dermatosis			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema nodosum			

subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Excessive granulation tissue			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scar pain			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Chronic kidney disease			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Fistula			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myositis			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal abscess			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall abscess			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess intestinal			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	0 / 53 (0.00%)	1 / 143 (0.70%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 53 (0.00%)	1 / 143 (0.70%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asymptomatic COVID-19			

subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	1 / 145 (0.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			

subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis listeria			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pilonidal cyst			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 53 (1.89%)	0 / 143 (0.00%)	1 / 145 (0.69%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal abscess			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 53 (0.00%)	1 / 143 (0.70%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			

subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrolyte imbalance			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 53 (0.00%)	0 / 143 (0.00%)	0 / 145 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Placebo Cohort 3	Etrolizumab/Etrolizumab 105mg	
Total subjects affected by serious adverse events			
subjects affected / exposed	8 / 96 (8.33%)	30 / 217 (13.82%)	
number of deaths (all causes)	0	1	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma pancreas			

subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral embolism			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Removal of foreign body from gastrointestinal tract			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Granuloma			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Drug hypersensitivity			

subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Female genital tract fistula			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic pain			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax spontaneous			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Blood creatinine increased			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test abnormal			

subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Gastrointestinal anastomotic leak			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural intestinal perforation			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thermal burn			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral gas embolism			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Tremor			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 96 (0.00%)	2 / 217 (0.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukocytosis			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Acute vestibular syndrome			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo positional			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Optic neuropathy			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 96 (1.04%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Crohn's disease			
subjects affected / exposed	3 / 96 (3.13%)	4 / 217 (1.84%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			

subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fistula			
subjects affected / exposed	0 / 96 (0.00%)	3 / 217 (1.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocutaneous fistula			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterovesical fistula			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer haemorrhage			
subjects affected / exposed	1 / 96 (1.04%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			

subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileal stenosis			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal fistula			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mechanical ileus			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proctitis			

subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal perforation			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subileus			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Acute febrile neutrophilic dermatosis			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erythema nodosum			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Excessive granulation tissue			

subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scar pain			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Chronic kidney disease			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal colic			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	1 / 96 (1.04%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fistula			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Myositis			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal abscess			
subjects affected / exposed	1 / 96 (1.04%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal wall abscess			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess intestinal			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal abscess			
subjects affected / exposed	0 / 96 (0.00%)	3 / 217 (1.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asymptomatic COVID-19			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			

subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	0 / 96 (0.00%)	2 / 217 (0.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis norovirus			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal infection			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis listeria			

subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pilonidal cyst			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 96 (0.00%)	2 / 217 (0.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal abscess			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal infection			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous abscess			

subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 96 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrolyte imbalance			
subjects affected / exposed	1 / 96 (1.04%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	0 / 96 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Etrolizumab 105mg Cohort 1	Placebo Cohort 1	Etrolizumab 105mg Cohort 2
Total subjects affected by non-serious adverse events			
subjects affected / exposed	61 / 120 (50.83%)	32 / 59 (54.24%)	80 / 176 (45.45%)
Nervous system disorders			
Headache			
subjects affected / exposed	13 / 120 (10.83%)	4 / 59 (6.78%)	20 / 176 (11.36%)
occurrences (all)	14	5	27
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 120 (2.50%)	2 / 59 (3.39%)	0 / 176 (0.00%)
occurrences (all)	3	2	0
General disorders and administration			

site conditions			
Fatigue			
subjects affected / exposed	4 / 120 (3.33%)	1 / 59 (1.69%)	6 / 176 (3.41%)
occurrences (all)	4	1	7
Injection site erythema			
subjects affected / exposed	5 / 120 (4.17%)	3 / 59 (5.08%)	9 / 176 (5.11%)
occurrences (all)	12	5	18
Pyrexia			
subjects affected / exposed	4 / 120 (3.33%)	0 / 59 (0.00%)	5 / 176 (2.84%)
occurrences (all)	4	0	5
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	6 / 120 (5.00%)	1 / 59 (1.69%)	14 / 176 (7.95%)
occurrences (all)	7	1	16
Crohn's disease			
subjects affected / exposed	9 / 120 (7.50%)	12 / 59 (20.34%)	13 / 176 (7.39%)
occurrences (all)	12	14	13
Diarrhoea			
subjects affected / exposed	2 / 120 (1.67%)	1 / 59 (1.69%)	1 / 176 (0.57%)
occurrences (all)	2	1	1
Dyspepsia			
subjects affected / exposed	5 / 120 (4.17%)	2 / 59 (3.39%)	4 / 176 (2.27%)
occurrences (all)	5	2	4
Frequent bowel movements			
subjects affected / exposed	1 / 120 (0.83%)	1 / 59 (1.69%)	1 / 176 (0.57%)
occurrences (all)	2	2	1
Nausea			
subjects affected / exposed	7 / 120 (5.83%)	4 / 59 (6.78%)	6 / 176 (3.41%)
occurrences (all)	8	4	6
Vomiting			
subjects affected / exposed	7 / 120 (5.83%)	2 / 59 (3.39%)	4 / 176 (2.27%)
occurrences (all)	9	2	5
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	2 / 120 (1.67%)	2 / 59 (3.39%)	2 / 176 (1.14%)
occurrences (all)	2	3	2

Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	6 / 120 (5.00%)	2 / 59 (3.39%)	12 / 176 (6.82%)
occurrences (all)	6	2	13
Back pain			
subjects affected / exposed	3 / 120 (2.50%)	1 / 59 (1.69%)	4 / 176 (2.27%)
occurrences (all)	3	1	4
Infections and infestations			
Influenza			
subjects affected / exposed	2 / 120 (1.67%)	2 / 59 (3.39%)	4 / 176 (2.27%)
occurrences (all)	2	2	4
Nasopharyngitis			
subjects affected / exposed	7 / 120 (5.83%)	2 / 59 (3.39%)	11 / 176 (6.25%)
occurrences (all)	7	2	12
Sinusitis			
subjects affected / exposed	1 / 120 (0.83%)	1 / 59 (1.69%)	2 / 176 (1.14%)
occurrences (all)	1	1	2
Upper respiratory tract infection			
subjects affected / exposed	6 / 120 (5.00%)	3 / 59 (5.08%)	11 / 176 (6.25%)
occurrences (all)	6	3	13
Urinary tract infection			
subjects affected / exposed	3 / 120 (2.50%)	0 / 59 (0.00%)	8 / 176 (4.55%)
occurrences (all)	3	0	9

Non-serious adverse events	Etrolizumab 210mg Cohort 1	Etrolizumab 210mg Cohort 2	Etrolizumab/Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	52 / 121 (42.98%)	68 / 174 (39.08%)	154 / 217 (70.97%)
Nervous system disorders			
Headache			
subjects affected / exposed	7 / 121 (5.79%)	20 / 174 (11.49%)	27 / 217 (12.44%)
occurrences (all)	10	22	43
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 121 (1.65%)	5 / 174 (2.87%)	10 / 217 (4.61%)
occurrences (all)	2	5	11
General disorders and administration site conditions			

Fatigue			
subjects affected / exposed	3 / 121 (2.48%)	2 / 174 (1.15%)	10 / 217 (4.61%)
occurrences (all)	3	2	11
Injection site erythema			
subjects affected / exposed	3 / 121 (2.48%)	7 / 174 (4.02%)	14 / 217 (6.45%)
occurrences (all)	7	14	41
Pyrexia			
subjects affected / exposed	4 / 121 (3.31%)	5 / 174 (2.87%)	16 / 217 (7.37%)
occurrences (all)	4	5	18
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	10 / 121 (8.26%)	10 / 174 (5.75%)	24 / 217 (11.06%)
occurrences (all)	12	16	29
Crohn's disease			
subjects affected / exposed	8 / 121 (6.61%)	7 / 174 (4.02%)	63 / 217 (29.03%)
occurrences (all)	9	7	66
Diarrhoea			
subjects affected / exposed	3 / 121 (2.48%)	2 / 174 (1.15%)	12 / 217 (5.53%)
occurrences (all)	3	2	15
Dyspepsia			
subjects affected / exposed	0 / 121 (0.00%)	2 / 174 (1.15%)	11 / 217 (5.07%)
occurrences (all)	0	2	11
Frequent bowel movements			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	2 / 217 (0.92%)
occurrences (all)	0	1	2
Nausea			
subjects affected / exposed	8 / 121 (6.61%)	11 / 174 (6.32%)	13 / 217 (5.99%)
occurrences (all)	14	14	16
Vomiting			
subjects affected / exposed	6 / 121 (4.96%)	3 / 174 (1.72%)	12 / 217 (5.53%)
occurrences (all)	8	3	22
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 121 (0.83%)	1 / 174 (0.57%)	4 / 217 (1.84%)
occurrences (all)	1	1	5
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	10 / 121 (8.26%)	9 / 174 (5.17%)	25 / 217 (11.52%)
occurrences (all)	10	11	30
Back pain			
subjects affected / exposed	4 / 121 (3.31%)	1 / 174 (0.57%)	10 / 217 (4.61%)
occurrences (all)	4	1	10
Infections and infestations			
Influenza			
subjects affected / exposed	1 / 121 (0.83%)	7 / 174 (4.02%)	15 / 217 (6.91%)
occurrences (all)	1	7	16
Nasopharyngitis			
subjects affected / exposed	9 / 121 (7.44%)	7 / 174 (4.02%)	27 / 217 (12.44%)
occurrences (all)	13	7	35
Sinusitis			
subjects affected / exposed	2 / 121 (1.65%)	4 / 174 (2.30%)	6 / 217 (2.76%)
occurrences (all)	2	4	9
Upper respiratory tract infection			
subjects affected / exposed	1 / 121 (0.83%)	7 / 174 (4.02%)	26 / 217 (11.98%)
occurrences (all)	1	7	30
Urinary tract infection			
subjects affected / exposed	6 / 121 (4.96%)	1 / 174 (0.57%)	13 / 217 (5.99%)
occurrences (all)	7	1	13

Non-serious adverse events	Placebo/Placebo	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3
Total subjects affected by non-serious adverse events			
subjects affected / exposed	33 / 53 (62.26%)	65 / 143 (45.45%)	45 / 145 (31.03%)
Nervous system disorders			
Headache			
subjects affected / exposed	4 / 53 (7.55%)	14 / 143 (9.79%)	8 / 145 (5.52%)
occurrences (all)	4	20	15
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 53 (3.77%)	5 / 143 (3.50%)	4 / 145 (2.76%)
occurrences (all)	2	5	4
General disorders and administration site conditions			
Fatigue			

subjects affected / exposed	1 / 53 (1.89%)	4 / 143 (2.80%)	5 / 145 (3.45%)
occurrences (all)	1	5	6
Injection site erythema			
subjects affected / exposed	2 / 53 (3.77%)	6 / 143 (4.20%)	5 / 145 (3.45%)
occurrences (all)	4	8	9
Pyrexia			
subjects affected / exposed	3 / 53 (5.66%)	6 / 143 (4.20%)	4 / 145 (2.76%)
occurrences (all)	3	8	4
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	9 / 53 (16.98%)	10 / 143 (6.99%)	6 / 145 (4.14%)
occurrences (all)	12	11	6
Crohn's disease			
subjects affected / exposed	13 / 53 (24.53%)	7 / 143 (4.90%)	8 / 145 (5.52%)
occurrences (all)	13	8	9
Diarrhoea			
subjects affected / exposed	2 / 53 (3.77%)	3 / 143 (2.10%)	6 / 145 (4.14%)
occurrences (all)	2	3	7
Dyspepsia			
subjects affected / exposed	2 / 53 (3.77%)	3 / 143 (2.10%)	1 / 145 (0.69%)
occurrences (all)	2	3	1
Frequent bowel movements			
subjects affected / exposed	3 / 53 (5.66%)	1 / 143 (0.70%)	0 / 145 (0.00%)
occurrences (all)	5	1	0
Nausea			
subjects affected / exposed	3 / 53 (5.66%)	6 / 143 (4.20%)	6 / 145 (4.14%)
occurrences (all)	7	6	7
Vomiting			
subjects affected / exposed	0 / 53 (0.00%)	4 / 143 (2.80%)	4 / 145 (2.76%)
occurrences (all)	0	4	4
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	3 / 53 (5.66%)	1 / 143 (0.70%)	2 / 145 (1.38%)
occurrences (all)	3	1	2
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	9 / 53 (16.98%)	11 / 143 (7.69%)	7 / 145 (4.83%)
occurrences (all)	12	12	8
Back pain			
subjects affected / exposed	5 / 53 (9.43%)	2 / 143 (1.40%)	0 / 145 (0.00%)
occurrences (all)	5	2	0
Infections and infestations			
Influenza			
subjects affected / exposed	2 / 53 (3.77%)	2 / 143 (1.40%)	0 / 145 (0.00%)
occurrences (all)	2	2	0
Nasopharyngitis			
subjects affected / exposed	3 / 53 (5.66%)	7 / 143 (4.90%)	9 / 145 (6.21%)
occurrences (all)	3	9	9
Sinusitis			
subjects affected / exposed	2 / 53 (3.77%)	4 / 143 (2.80%)	2 / 145 (1.38%)
occurrences (all)	2	4	2
Upper respiratory tract infection			
subjects affected / exposed	3 / 53 (5.66%)	5 / 143 (3.50%)	4 / 145 (2.76%)
occurrences (all)	3	5	6
Urinary tract infection			
subjects affected / exposed	1 / 53 (1.89%)	1 / 143 (0.70%)	2 / 145 (1.38%)
occurrences (all)	1	1	2

Non-serious adverse events	Placebo Cohort 3	Etrolizumab/Etrolizumab 105mg	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	35 / 96 (36.46%)	147 / 217 (67.74%)	
Nervous system disorders			
Headache			
subjects affected / exposed	7 / 96 (7.29%)	22 / 217 (10.14%)	
occurrences (all)	10	27	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 96 (2.08%)	11 / 217 (5.07%)	
occurrences (all)	2	12	
General disorders and administration site conditions			
Fatigue			

subjects affected / exposed	3 / 96 (3.13%)	13 / 217 (5.99%)	
occurrences (all)	5	15	
Injection site erythema			
subjects affected / exposed	0 / 96 (0.00%)	7 / 217 (3.23%)	
occurrences (all)	0	16	
Pyrexia			
subjects affected / exposed	2 / 96 (2.08%)	7 / 217 (3.23%)	
occurrences (all)	2	7	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	13 / 96 (13.54%)	27 / 217 (12.44%)	
occurrences (all)	15	34	
Crohn's disease			
subjects affected / exposed	3 / 96 (3.13%)	37 / 217 (17.05%)	
occurrences (all)	3	43	
Diarrhoea			
subjects affected / exposed	3 / 96 (3.13%)	21 / 217 (9.68%)	
occurrences (all)	3	22	
Dyspepsia			
subjects affected / exposed	1 / 96 (1.04%)	8 / 217 (3.69%)	
occurrences (all)	1	8	
Frequent bowel movements			
subjects affected / exposed	1 / 96 (1.04%)	1 / 217 (0.46%)	
occurrences (all)	1	1	
Nausea			
subjects affected / exposed	8 / 96 (8.33%)	21 / 217 (9.68%)	
occurrences (all)	11	28	
Vomiting			
subjects affected / exposed	2 / 96 (2.08%)	14 / 217 (6.45%)	
occurrences (all)	3	16	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	4 / 96 (4.17%)	7 / 217 (3.23%)	
occurrences (all)	4	7	
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	7 / 96 (7.29%)	27 / 217 (12.44%)	
occurrences (all)	7	32	
Back pain			
subjects affected / exposed	3 / 96 (3.13%)	4 / 217 (1.84%)	
occurrences (all)	3	5	
Infections and infestations			
Influenza			
subjects affected / exposed	1 / 96 (1.04%)	6 / 217 (2.76%)	
occurrences (all)	1	6	
Nasopharyngitis			
subjects affected / exposed	4 / 96 (4.17%)	32 / 217 (14.75%)	
occurrences (all)	4	42	
Sinusitis			
subjects affected / exposed	1 / 96 (1.04%)	13 / 217 (5.99%)	
occurrences (all)	1	16	
Upper respiratory tract infection			
subjects affected / exposed	1 / 96 (1.04%)	16 / 217 (7.37%)	
occurrences (all)	1	19	
Urinary tract infection			
subjects affected / exposed	0 / 96 (0.00%)	11 / 217 (5.07%)	
occurrences (all)	0	18	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
14 October 2014	V2
09 December 2014	V3
07 October 2015	V4
18 November 2016	V5
31 August 2017	v6
24 April 2019	v7

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

http://www.ncbi.nlm.nih.gov/pubmed/34467254

http://www.ncbi.nlm.nih.gov/pubmed/32445184

http://www.ncbi.nlm.nih.gov/pubmed/32464142